Dear Colleagues,

This Special Issue focuses on a spectrum of major diseases linked by common inflammatory pathways, including multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, asthma, chronic obstructive pulmonary disease, and systemic lupus erythematosus. Although their etiologies differ, these conditions share core pathological mechanisms that lead to target organ damage and widespread systemic effects. The purinergic signaling system—an intricate network comprising extracellular nucleotides/nucleosides, their P1 and P2 receptors, metabolic enzymes, and transporters—has emerged as a central hub regulating immunity, inflammation, and organ function. It plays pivotal roles in both physiological and pathological processes and represents a promising target for pharmacological intervention.

This Special Issue aims to provide a comprehensive overview of the multifaceted role of purinergic signaling in related diseases, dissect its underlying cellular and molecular mechanisms, and highlight the translational prospects in this field. We place particular emphasis on the development and therapeutic potential of novel pharmacological agents targeting the purinergic pathway. These agents offer innovative therapeutic strategies for the diseases listed above.

By bringing together cutting-edge reviews and research articles, this Special Issue seeks to provide researchers with a timely update on the field and stimulate further innovation in drug discovery targeting the purinergic system.

We invite the submission of original research articles and reviews that align with this theme.

Prof. Dr. Robson Xavier Faria
Guest Editor